Lung Cancer

Lung cancer is a heterogenous disease compromising of several subtypes including non-small cell lung carcinoma (NSCLC), adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Recent advances in molecular techniques has enabled the identification of molecular abnormalities leading to emergence of personalized treatment strategies.

Mutations, gene rearrangements, amplification and deletion are the main molecular alteration seen in lung cancer.

biosimilars

Key NSCLC biomarkers

EGFR ALK ROS1 HER2 RET MET BRAF PIK3CA NTRK1 FGFR DDR2

Key Adenocarcinoma biomarkers

KRAS EGFR MET ALK NTRK1 FGFR HER2 ROS BRAF PIK3CA RET DDR1

Key Squamous Cell Carcinoma biomarkers

FGFR PTEN PIK3CA KRAS DDR2 EGFR MET

Lung cancer tissue controls

Frozen sections Tissue Protein Lysates Total RNA FFPE sections Genomic DNA Tissue Scan

In addition to other tools, OriGene has the largest collection Mutant ORF Clones, Ultra specific antibodies (UltraMAB), CytoSections (Control for IHC, ICC) and other tools for genes associated with lung cancer.

References:

  1. Villalobos et al, 2017 Feb; 31(1): 13–29. doi: 10.1016/j.hoc.2016.08.006
  2. Pakkala et al., 2018 Aug 9;3(15):e120858.  doi:10.1172/jci.insight.120858
  3. Goebel et al.; 2020 July 1 11 (7): doi:10.1039/d0md00096e
  4. Ryan et al., 2018 Nov 15 (11): doi:10.1038/s41571-018-0105-0
  5. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017 Jan 19;18(1):197. doi:10.3390/ijms18010197 PMID: 28106826; PMCID: PMC5297828.https://pubmed.ncbi.nlm.nih.gov/28106826/.